Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study

Carlos A. Aguilar-Salinas, Francisco J. Gómez-Pérez, Carlos Posadas-Romero, Cuauhtémoc Vázquez-Chávez, Eduardo Meaney, Alfonso Gulías-Herrero, Luz E. Guillén, Alma Alvarado Vega, Enrique Mendoza Pérez, Luis Eduardo Romero-Nava, Rita Angélica Gómez-Díaz, Saúl Salinas-Orozco, Rafael Moguel, Germán Novoa

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease. The aim of this trial was to evaluate the efficacy and safety of once-daily atorvastatin 10-80 mg for the treatment of hyperlipidemia in type 2 diabetics with plasma low-density lipoprotein cholesterol (LDL-C) levels exceeding 3.4 mmol/l (130 mg/dl). One hundred and two patients met the study criteria and received 10 mg/day atorvastatin. Patients who reached the target LDL-C level of ≤2.6 mmol/l (100 mg/dl) maintained the same dosage regimen until they had completed 16 weeks of treatment. Patients not reaching the target LDL-C underwent dose titration to atorvastatin 20, 40 and 80 mg/day at Weeks 4, 8 and 12, respectively. All 88 patients who completed the study attained target LDL-C levels and 52 (59%) of patients achieved the target goal at the starting dose of atorvastatin 10 mg/day. In this group the differences between baseline and post-treatment values for LDL-C were 4.3±0.7 mmol/l (166±26 mg/dl) versus 2.2±0.4 mmol/l (87±14 mg/dl) (P<0.0001), respectively, a decrease of 47%. Similar trends were observed for total cholesterol, triglycerides, very low-density lipoprotein cholesterol and apolipoprotein B levels. The safety profile of atorvastatin in these patients was highly favorable and similar to those reported with other statins. Only one patient withdrew due to a possible drug-related adverse event. These data confirm the marked efficacy and safety of atorvastatin in type 2 diabetic patients with hyperlipidemia and the efficacy of atorvastatin 10 mg in helping patients attain their LDL-C goal. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)489-496
Number of pages8
JournalAtherosclerosis
Volume152
Issue number2
DOIs
StatePublished - Oct 2000

Keywords

  • Atorvastatin
  • Hypercholesterolemia
  • Low-density lipoprotein cholesterol
  • Triglyceride
  • Type 2 diabetes mellitus

Fingerprint

Dive into the research topics of 'Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study'. Together they form a unique fingerprint.

Cite this